Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. Show more

Location: 601 Gateway Boulevard, South San Francisco, CA, 94080, United States | Website: https://akerotx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

4.098B

52 Wk Range

$21.02 - $58.40

Previous Close

$51.41

Open

$51.16

Volume

813,654

Day Range

$51.08 - $52.60

Enterprise Value

3.604B

Cash

686.3M

Avg Qtr Burn

-65.66M

Insider Ownership

1.37%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.